Show simple item record

dc.contributor.authorGermetaki, Theodora
dc.contributor.authorNicholls, Camille
dc.contributor.authorAdams, R. A.
dc.contributor.authorBraun, Michael S
dc.contributor.authorRogan, Jane
dc.contributor.authorMoghadam, Sharzad
dc.contributor.authorLenfert, E.
dc.contributor.authorLukas, A.
dc.contributor.authorEdelstein, D. L.
dc.contributor.authorJones, F. S.
dc.contributor.authorSaunders, Mark P
dc.date.accessioned2020-08-17T07:21:41Z
dc.date.available2020-08-17T07:21:41Z
dc.date.issued2020en
dc.identifier.citationGermetaki T, Nicholls C, Adams RA, Braun M, Rogan J, Moghadam S, et al. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncol. 2020.en
dc.identifier.pmid32716216en
dc.identifier.doi10.2217/fon-2020-0523en
dc.identifier.urihttp://hdl.handle.net/10541/623202
dc.description.abstractAim: To determine the concordance between plasma and tissue RAS mutation status in metastatic colorectal cancer patients to gauge whether blood-based testing is a viable alternative. We also evaluated the change in mutation status on progression. Materials/methods: RAS testing was performed on plasma from patients commencing first-line therapy (OncoBEAM™ RAS CEIVD kit). Results were then compared with formalin-fixed paraffin embedded tumor samples. Results: The overall percentage agreement (concordance) was 86.0% (86/100), which demonstrates that blood-based testing is an alternative to tissue-based testing. Reproducibility was 100% between three laboratories and 20% showed changes in their RAS mutational status on progression. Conclusion: These results show good concordance between tissue and plasma samples and suggest the need for longitudinal plasma testing during treatment to guide management decisions. Keywords: BEAMing; RAS; circulating-free DNA; colon cancer; ctDNA; mCRC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/fon-2020-0523en
dc.titleBlood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progressionen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical & Clinical Oncology, The Christie Hospital, 550 Wilmslow Road, Manchester M20 4BXen
dc.identifier.journalFuture Oncologyen
dc.description.noteen]
refterms.dateFOA2020-08-17T12:39:36Z


Files in this item

Thumbnail
Name:
32716216.pdf
Size:
2.701Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record